Efficacy Trial for the Reduction of Glabellar Lines

Inclusion criteria

• Glabellar lines rating of at least two per the Merz Scale
• Written informed consent
• Understands and accepts the following obligations during the follow-up period (minimum of three months and up to one year)
• available for the 3 day phone call and present for each follow-up visit;
• receive NO other facial procedures in the upper face for a minimum of three months and up to one year after the RF procedure;
• make NO changes to the eyebrows for a minimum of three months after the RF procedure.

Exclusion criteria

• Injection of botulinum toxin to the upper face within the previous four months
• Use of fillers in the upper face within the previous twelve months
• Use of prescription treatments (e.g., Renova, Retin-A, micro-dermabrasion, chemical peels) on the upper face, in the area between the eyebrows where frown lines occur, within the previous four weeks or plans to use these treatments during the study
• Facial or skin conditions that could interfere with treatment or confound results (e.g., signs or symptoms of eyebrow or eyelid ptosis, facial nerve palsy, scarring, infection)
• Implanted pacemaker or automatic implantable cardioverter/defibrillator
• History of keloid formation
• Known bleeding disorder
• Use of thrombolytics, anticoagulants, aspirin or non-steroidal anti-inflammatory drugs within seven days prior to study treatment Is receiving systemic corticosteroids or anabolic steroids (standard doses of inhaled or nasal corticosteroids are acceptable)
• History of chronic or recurrent infection, or compromised immune system
• Known lidocaine hypersensitivity
• Enrollment in another research study
• Pregnant, or plans to get pregnant during the follow-up period
• Any other condition or circumstance that might either pose a risk, in the investigator's opinion, to the subject or interfere with the ability to acquire satisfactory clinical data throughout the follow-up period